Evaluation of Rifalazil in a Combination Treatment Regimen as an Alternative to Isoniazid-Rifampin Therapy in a Mouse Tuberculosis Model

The newer rifamycin, rifalazil (RLZ) (previously known as KRM-1648), has been shown in prior experiments to be a highly potent drug against Mycobacterium tuberculosis. In this report, we studied the efficacy of RLZ in combination with pyrazinamide (PZA) and ethambutol (EMB) in a long-term in vivo ex...

Descrizione completa

Dettagli Bibliografici

Pubblicato in:	Antimicrob Agents Chemother
Autori principali:	Lenaerts, Anne M., Chase, Sharon E., Cynamon, Michael H.
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	American Society for Microbiology (ASM) 2000
Soggetti:	Experimental Therapeutics
Accesso online:	https://ncbi.nlm.nih.govhttps://pmc.ncbi.nlm.nih.gov/articles/PMC101623/ https://ncbi.nlm.nih.govhttps://pubmed.ncbi.nlm.nih.gov/11036043/ https://ncbi.nlm.nih.govhttps://doi.org/10.1128/aac.44.11.3167-3168.2000
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!